A Study of CDX-585 in Patients With Advanced Malignancies
← catalyst calendarSponsored by Celldex Therapeutics (industry) · CLDX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20actual
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-11 | actual | When the study began enrolling |
| Primary completion | 2025-05-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-21 | actual | The whole study's end, after follow-up |
| First posted | 2023-03-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non-small Cell Lung Cancer
- Gastric Cancer
- Head and Neck Cancer
- Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Bladder Urothelial Carcinoma
- Colorectal Cancer
- Esophageal Cancer
- Hepatic Cancer
- Renal Cell Carcinoma
- Cholangiocarcinoma
- Pancreatic Cancer
- Other Solid Tumors
Intervention
- Drug: CDX-585
Primary outcomes
what the primary-completion date above is the date OFDose escalation: To determine the maximum tolerated dose of CDX-585 and to select the CDX-585 dose(s) for evaluation in tumor-specific expansion cohorts
measured Approximately 12 months
Tumor-specific expansion cohorts: To further evaluate the safety of CDX-585 by tumor type.
measured Approximately 6 months
Permalink · CLDX's whole pipeline · Catalyst calendar · Every registered study · What changed